Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avosentan for diabetic nephropathy in type 2 diabetes mellitus
2005-000604-14Phase 3Terminated
- Sponsor
- Speedel
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic glomerulosclerosis comparing Avosentan with Placebo (2 arms). Primary endpoint: Time to composite renal endpoint. Started Apr 2005; status: terminated.
02
Drugs
avorsentan
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2005-000604-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000604-14.